The Neuro-Cells® technology platform addresses a multi-billion market as it targets the common cellular pathway of multiple neurodegenerative diseases, that will affect 115 million people by 2025, that pressure healthcare expenditure heavily, and for which no effective treatment exists.

 

Neuroplast holds European Orphan Designations with a fast-track development path to market authorization, with ten-year market exclusivity, for traumatic spinal cord injury and frontotemporal dementia.

​

Safety is proven for traumatic spinal cord injury and efficacy is studied in a running combined phase II-III clinical trial.

​

Further evidence suggests application potential for traumatic brain injury, ALS, MS, and Parkinson's disease.

​

We value our stakeholders and invite you to become part of our mission to give back perspective.

​

Please contact us via Hans de Munter (h.demunter@neuroplast.com)